Introduction/Background Non-epithelial rare germ cell tumors (GCT) and sex cord stromal tumors (SCST) are mainly associated with long survival. The treatment includes surgery, frequently combined with chemotherapy (CT). The French Rare Malignant Gynecological Tumors (TMRG)/GINECO case-control VIVROVAIRE Rare tumors study already reported the QOL among survivors, treated with surgery +CT, compared to age-matched healthy women (HW). Looking to the different clinical profile of pts, we intend to describe the long-term fatigue according to subtype of cancers (SCST, GCT).

Methodology Non-epithelial ovarian cancer survivors (nEOCS), cancer-free ≥2 years after treatment, were identified from the TMRG Network. HW were issued from the ‘Seintinelles’ research platform. Primary endpoint was chronic fatigue (MFI) compared between patients (SCST/GCT) versus HW. A minimal 5% difference for the score between groups was considered as clinically relevant.

Results 97 SCST and 120 GCT were included. Patients characteristics are detailed in table I. SCST patients were older than GCT and mostly FIGO stage I of favorable prognosis Median delay from the end of treatment was 6 yrs. In univariate analysis, among SCST treated with CT, levels of general fatigue were significantly higher compared with HW (MFI general fatigue median score 27.0 [IQR: 21.0–31.0] vs 23.0 [17.3–27.8], p= 0.02). Among GCT treated with CT, fatigue was not different from HW (MFI general fatigue median score 24.0 [20.0–29.0] vs 23.0 [18.0–30.0], p= 0.592). After adjustment on age, schooling, BMI, insomnia and physical activity (IPAQ), fatigue remained significantly higher for all SCST, compared with all HW (beta= 1.67 ; p = 0.026); but not for SCST compared with age-matched HW (p=0.098).

Conclusion SCST patients (older pts compared to GCT) have long-term fatigue more than 6yrs after the end of treatments, which was not observed for GCT patients. This long-term fatigue need to be integrated in the follow-up care plan of nEOCS.

Disclosures Coraline Dubot: MSD, Eisai

Isabelle Ray Coquard: Type of affiliation/financial interest Name of commercial company/details

Receipt of grants/research supports:

• MSD, Roche and BMS;

Research grant/funding (institution) from MSD, Roche, BMS, GSK, Novartis, Astra Zeneca and Merck Sereno

Receipt of honoraria or consultation fees:

• Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Tesaro and Clovis;

• Abbvie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; Springworks, Adaptimmune, Immunogen, Seagen, Novocure, Daichi Sankyo,

Travel support from Roche, AstraZeneca and GSK

Patricia Pautier: grants from MSD and Onxeo; honoraria for lectures from MSD, PharmaMar and Seagen; honoraria for expert testimony from MSD; honoraria for advisory board membership from PharmaMar, Genmab, Roche, GSK, MSD, and Seagen; and support for attending meetings or travel from PharmaMar, Amgen, Ose Immuno, Seagen, AstraZeneca, and GSK.

Justine Lequesne: none

Tiphaine Renaud: none

Frederic Selle: Astra Zeneca (Advisory Board, Invited Speaker), GSK/Tesaro (Advisory Board, Invited Speaker), MSD (Advisory Board, Invited Speaker), Eisai (Invited speaker)

Dominique Berton-Rigaud: none

Sophie Frank: none

Thibault De La Motte Rouge: Astra-Zeneca; Clovis Oncology; Eisai; MSD; Myriad; Novartis; Natera; Pfizer; Roche; Sanofi; Seagen; GSK

Elsa Kalbacher: none

Magali Provansal: none

Cyriac Blonz: none

Hubert Orfeuvre: none

Jérôme Alexandre: AstraZeneca, Eisai, MSD, GSK, Janssen, Pfizer, Clovis.

Paule Augereau: astrazeneca, DAICHI, novartis, MSD, GSK

Jean-Emmanuel Kurtz: AstraZeneca, Chugai-Pharma, Clovis Oncology, Dragonfly Therapeutics, EISAI, GSK, Mersana, MSD, Roche, Pharmamar, Tesaro.

Jean-Michel Grellard: none

Benedicte Clarisse: none

François Gernier: none

Florence Joly: Amgen Invited Speaker, Personal

,Astellas Advisory Board, Personal

,AstraZeneca Advisory Board, Personal

,AstraZeneca Invited Speaker, Personal

,Bayer Advisory Board, Personal

,ESAI Invited Speaker, Personal

,Esai Advisory Board, Personal

,esai Invited Speaker, Personal

,GSK Advisory Board, Personal

,GSK Invited Speaker, Personal

,Ipsen Invited Speaker, Personal

,ipsen Advisory Board, Personal

,Janssen Invited Speaker, Personal

,Janssen Advisory Board, Personal

,MSD Invited Speaker, Personal

,MSD Advisory Board, Personal

,Novartis/3A Invited Speaker, Personal

,novocure Advisory Board, Personal

,pfizer Advisory Board, Personal

,seagen Advisory Board, Personal

,viatris Invited Speaker, Institutional

,astellas Research Grant, Institutional, No financial interest

,AstraZeneca Coordinating PI, Institutional, No financial interest

,BMS Research Grant, Institutional, No financial interest

,GSK Coordinating PI, Institutional, No financial interest

,janssen Funding, Institutional, No financial interest